Open Access<p>Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China</p>
Author(s) -
Wanren Peng,
Fenglin Zhang,
Zishu Wang,
Dongliang Li,
Yong He,
Ning Zong,
Lili Sheng,
Jidong Wang,
Xiaoyang Xia,
Changjun Yu,
Zi-An Wang,
Yong Zhao,
Hui Liang,
Bing Hu,
Cuiling Sun,
Daoqin Wang,
Yunsheng Cheng,
Ming Pan,
Liming Xia,
Xinglai Guo,
Yanshun Zhang,
Zhiqiang Hu,
Xinzhong Li,
Longnian Lin,
Jun Zhang,
Hong Qian,
Hua Xie,
Guan Sun
Publication year - 2020
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s249153
Subject(s) - apatinib , medicine , clinical endpoint , oncology , cancer , population , bevacizumab , chemotherapy , clinical trial , environmental health
In China, gastric cancer (GC) ranks second in incidence and mortality. Over 80% of patients with GC were diagnosed at an advanced stage with poor clinical outcome. Chemotherapy was the mainstream treatment with limited benefit. Apatinib, an inhibitor of targeting vascular endothelial growth factor receptor 2 (VEGFR2), has been approved for third-line treatment of advanced gastric cancer. However, the data of apatinib treatment in the real-world setting are limited. In this real-world study, we aimed to understand the current treatment pattern of apatinib, investigate the effectiveness and safety of apatinib in real-world settings, and explore the potential factors associated with the clinical outcomes.